MediCom Worldwide, Inc. is pleased to have collaborated with the MDS Foundation on the development of this activity. Myelodysplastic syndromes are a group of small-incidence malignancies that represent a significant challenge to many community oncologists. In this activity, participants will hear from two key experts about a variety of topics including, but not limited to: personalized risk stratification, iron overload, immunotherapies, and new strategies for treating lower- and higher-risk MDS. Join Dr. Sekeres and Dr. Steensma as they discuss incorporating molecular abnormalities into diagnosis and prognosis, and where luspatercept and imetelstat may fit into the future of MDS treatment.

For more information on managing your patients with MDS, please view the Newsletter Resource available here.